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Background: Opioid substitution treatment seems to improve adherence to highly active antiretroviral
therapy (HAART) in drug users (DU). DU in Amsterdam receive methadone within a harm reduction pro-
gramme.We hypothesized that not only receiving methadone, but joining this complete comprehensive
programme would improve HAART adherence.
Methods: Included were 102 HIV-positive DU attending the Amsterdam Cohort Study (ACS), reporting
HAART use at multiple visits between 1999 and 2009. Non-adherence was deﬁned as taking less than
95% of medication in the past 6 months (self-reported). Harm reduction intensity (HR) was measured by
combining injectingdruguse,methadonedosage andneedle exchange, in different levels of participation,
ranging fromno/incomplete HR, complete HR to lowor no dependence onHR.We studied the association
between non-adherence and harm reduction intensities with logistic regression models adjusted for
repeated measurements.
Results: Non-adherence was reported in 11.9% of ACS visits. Non-injecting DU with low dependence on
HR were less adherent than DU with complete HR (aOR 1.78; CI 95% 1.00–3.16), although there was
no overall effect of HR. No difference was demonstrated in adherence between DU with complete HR
and incomplete HR. Unsupervised housing (no access to structural support at home) (aOR 2.58; CI 95%
1.40–4.73) and having a steady partner (aOR 0.48; CI 95% 0.24–0.96) were signiﬁcantly associated with
respectively more and less non-adherence.
Conclusions: InAmsterdam, still-injectingDUwhoareexposed to systematic and integratedcare, although
not practising complete harm reduction, can be just as adherent to HAART as DU who make use of
complete harm reduction and non-injecting DU with no dependence on harm reduction. These ﬁndings
suggest the importance of a systematic and comprehensive support system including supervised housing
and social and medical support to increase HAART adherence rates amongst all HIV-infected DU. When
oduc
ttingssuchprogrammes are intr
for drug users in these se
ntroduction
Since the introduction of highly active antiretroviral therapy
HAART), studies concerning the social and behavioural aspects of
IV have extended their interest to aspects that have impact on
IV treatment, such as HAART adherence. High adherence rates
re necessary to attain sustained HIV viral load suppression and
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prevent drug resistance (Bangsberg, 2006; Paterson et al., 2000;
Shuter, Sarlo, Kanmaz, Rode, & Zingman, 2007).
The negative perception of physicians about HAART adherence
amongst drug users is one of the reasons drug users still have
less and later access to HAART compared to non-drug using HIV-
patients (Bogart, Kelly, Catz, & Sosman, 2000; WHO, 2003; WHO,
2007). Although the clinical beneﬁts of HAART treatment in drug
users related to HIV-speciﬁc death have shown to be present as in
other HIV-patients (Smit, Geskus, et al., 2006), drug users eventu-
Open access under the Elsevier OA license.ally beneﬁt less fromHAARTon the population level, partly because
of the barrier to HAART access.
Several studies indeed demonstrate an association between
drug use and non-adherence (Arnsten et al., 2002; Hinkin et al.,
2007; Kerr et al., 2005; Knowlton et al., 2006; Lucas, Cheever,
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haisson, & Moore, 2001; UNAIDS, 2007). The treatment of illicit
rug use with opioid substitution has therefore been proposed as a
trategy that may not only lower the HIV incidence in combination
ith other harm reduction components (van den Berg, Smit, Van
russel, Coutinho, & Prins, 2007), but may also be a determinant
hat positively inﬂuences adherence to HAART, and it has proven
o be so in several studies (Clarke et al., 2003; Hicks et al., 2007;
apadia et al., 2008; Palepu et al., 2006; Roux et al., 2008; Smit,
indenburg, et al., 2006). Its effect varies though as to the structure
f care (Palepu et al., 2006) and whether the patient is a former or
current user of illicit drugs (Hicks et al., 2007).
In the Amsterdam Cohort Study (ACS) amongst drug users, we
ollow drug users who have access to HIV care and drug addic-
ion care outside the cohort setting. Drug addiction care consists of
pioid substitution treatment with methadone, needle exchange
rogrammes (NEP), and medical and social care. The intensity of
ontact with the health care system and the kind of health care
drug user receives depends on the level of drug dependence
nd personal ‘stability’ of the drug user, deﬁned by, e.g. (psychi-
tric) comorbidity, social network and housing situation and the
evel of ﬁnancial independence. The result is a low-threshold indi-
idualized treatment approach with different intensities of harm
eduction in which active drug use is not considered an exclusion
riterion for treatment.
We previously demonstrated that full participation in such a
arm reduction programme, and not the use of needle exchange
rogrammes or methadone alone, is associated with a lower
IV and HCV incidence, indicating that combined prevention
easures are effective (van den Berg et al., 2007). Here, we
ypothesized that full participation in such a comprehensive harm
eduction programme including medical and social care would
mprove adherence to HAART. The current study therefore aimed
o investigate determinants that inﬂuence adherence to HAART in
IV-positive drug users in Amsterdam, and speciﬁcally their usage
f different intensities of harm reduction.
ethods
tudy population and design
The ACS amongst drug users is an open, prospective cohort
tudy. It was initiated in 1985 to study the epidemiology of HIV
nd other bloodborne and sexually transmitted infectious diseases
nd to evaluate the effects of interventions, such as prevention and
reatment. The recruitment of participants is still ongoing (van den
oek, Coutinho, van Haastrecht, van Zadelhoff, & Goudsmit, 1988).
articipation in the cohort is voluntary, and informed consent is
btained. During the study period of 1999–2009, inclusion crite-
ia consisted of: having a history of regular illicit drug use, either
njecting or non-injecting, living in the Netherlands, being moti-
ated to participate in the study every 6 months and accepting to
eceive HIV-test results. Participants receive a ﬁnancial compen-
ation at every follow-up visit. At study entry and follow-up visits
very 6 months, the participant answers standardized questions
sked by a trained nurse. Questions concern demographics, drug
ehaviour, sexual behaviour, and medical history, including HIV-
nddrug-addiction treatment,medication and adherence, all refer-
ing to the time-periodbetween the current andprevious visit (past
ix months).
Each visit a blood sample is drawn for HIV testing and storage.
or HIV-positive participants, viral load is tested, using Nuclisens
IV1 QT until 2006 and, thereafter, M2000rt (Abbott). The CD4
ount is determined using ﬂow cytometry.
The present study included participants who were HIV-
ositive and were prescribed HAART during the period ofl of Drug Policy 22 (2011) 210–218 211
January 1999 (start collection of adherence-data) until February
2009.
Whether a participant used HAART or not was based on self-
report and conﬁrmed by checking clinical data from medical
records received after hospital admission and yearly matching
against the national HIV register.
Deﬁnition of variables
Rates of non-adherence toHAARTwere self-reportedby thepar-
ticipant to the study nurse and are based on the number of days
that medication was not taken in the last 6 months. The reported
number was subsequently recorded as one of four categories. To
calculate the percentage of non-adherence in the last 6months the
number of days in the category was divided by 6 months. For our
analyses a participant was considered non-adherent if taking less
than 95% of the prescribed medication (Paterson et al., 2000).
To study the impact of different intensities of harm reduction on
adherence, we combined three main determinants of harm reduc-
tion intensity in our cohort: injecting of drugs (IDU) or not, use of a
needle exchange programme (in which irregular needle exchange
means less than 100% of needles exchanged) and methadone-
dosage. We assumed 80mg/day as the minimum sufﬁcient dosage
to achieve harm reduction (Arroyo et al., 2007; Clarke et al., 2001;
Hinkin et al., 2007).
With these determinants we deﬁned four categories of harm
reduction intensity, comparable to those previously associated
with HIV and HCV incidence (van den Berg et al., 2007):
‘No/incomplete harm reduction’ deﬁned as injecting drugs in
past 6 months, no needle exchange and no methadone/injecting
drugs in past 6 months, any methadone dose and no or irreg-
ular needle exchange; or injecting drugs in past 6 months and
lowmethadone dose and always needle exchange, ‘complete harm
reduction’ deﬁned as injecting drugs, high methadone dosage
(≥80mg/day) and full needle exchange; or not injecting drugs
and high methadone dosage, ‘low dependence on harm reduc-
tion’ deﬁned as not injecting drugs, low methadone dosage
(<80mg/day), and ‘no dependence on harm reduction’ deﬁned as
not injecting drugs, no methadone.
Statistical analysis
Chi-square test and Mann–Whitney’s U-test were used to com-
pare characteristics of HIV-positive DU receiving HAART on their
ﬁrst HAART ACS visit after 1998 and characteristics of those never
receiving HAART on their ﬁrst ACS visit after 1998. CD4 count and
viral load were compared between the ﬁrst HAART visit of HAART-
users and the last visit of non-HAART users. General characteristics
that were evaluated besides harm reduction intensity in the past 6
months included sex, age at visit, ethnicity, having a steady partner
in the past 6 months, housing situation in the past 6 months, drug
use (frequency, type of drugs, mode of use) in the past 6 months,
methadone use in the past 6 months, needle exchange use in the
past 6 months, viral load as measured at visit, CD4 count as mea-
sured at visit.
The Kaplan–Meier method was used to estimate the cumula-
tive incidence of non-adherence. Follow-up time was calculated
from the date of the ﬁrst visit on HAART until the earliest of: non-
adherence, loss to follow-up, or the censoringdate (February 2009).
To test differences in percentages of viral load and CD4 count
between adherent persons and non-adherent persons, stratiﬁed by
harm reduction intensity, we used univariate logistic regression.
Finally, univariate and multivariate logistic regression was used to
study the association between harm reduction intensity and non-
adherence (the reference category being complete harm reduction,
because of group size), and other potential determinants and
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on-adherence. Generalized Estimating Equations (GEE) (Zeger &
iang, 1986), using the exchangeable working correlation matrix,
ere applied to all logistic regression analyses to correct for
epeated measurements within individuals.
Since we were primarily interested in the independent role
f harm reduction intensity, this variable was always included in
ur ﬁrst multivariate model. We also always included calendar
ear, since intake of HAART medication became less complex over
ime, which might have inﬂuenced adherence. We extended this
odel with considering all other variables with a p-value≤0.10
n univariate analysis and/or variables assumed to be related to
on-adherence (based on the literature: having a steady partner
Carrieri et al., 2006; Knowlton et al., 2007), housing situation
Leaver, Bargh, Dunn, & Hwang, 2007), and gender (Arnsten et al.,
002, 2007)) for entry in our ﬁnal model. This multivariate model
as built using a stepwise backward strategy. In our ﬁnal model,
e checked for interaction between variables and for confounding.
p-value≤0.05 was considered statistically signiﬁcant.
Besides harm reduction intensity, we studied the effects of
he underlying individual components of the harm reduction pro-
ramme (IDU,methadonedosage,NEP) andnon-injecting druguse.
herefore we conducted a secondmultivariate analysis to evaluate
he separate effect of these variables.
All analyses were conducted using SPSS 15, STATA 9.2 and R 2.7.
esults
haracteristics
Between January 1999 and February 2009, 934 drug users were
ollowed in the ACS, ofwhom157wereHIV-positive. In this period,
02 of the HIV-positive drug users reported using HAART of whom
01 answered questions about adherence to HAART.
The CD4 counts of HIV-positive drug users that did not use
AART (n=55), as measured on their last visit in the studied
eriod (median 250 cells/l, IQR 280), were comparable to the CD4
ounts of those using HAART, as measured on their ﬁrst HAART-
isit (median 250 cells/l, IQR 233). However, the drug users never
eceiving HAART had signiﬁcantly higher viral load levels (median
4,000 copies/mL IQR 113250 vs. median 400 copies/mL IQR 950).
articipants never receiving HAART also were signiﬁcantly more
ikely to have injected drugs and to have joined an incomplete
arm reduction programme in the past 6 months. In addition, they
eceived methadone less often (borderline signiﬁcance) compared
o those participants on HAART (data not shown).
Of the 102 HIV-positive drug users using HAART, the total num-
er of visits since 1998 was 1376, of which 733 were HAART-visits.
he median number of HAART-visits since 1998 was 5 (IQR 6), and
edian time of follow-up since the ﬁrst HAART-visit was 3 years
IQR 4.6) (see Table 1). Themedian time betweenHAART-visitswas
81 days (IQR 102).
Included were 71 men and 31 women, and mean age was 42.3
ears (SD 6.4 years). The majority (92.2%) reported having ever
njected illicit drugs (deﬁned by usage of heroin, cocaine or speed-
all, a mix of both). Of all participants, 31.4% reported having
njected illicit drugs in the 6 months preceding their ﬁrst HAART-
isit, and 65.7% reported having used illicit drugs in a non-injecting
anner. The majority (89.2%) used methadone in some dosage.
According to our harm reduction intensity deﬁnitions, 14.7% ofarticipants were included in the no/incomplete harm reduction
ategory at their ﬁrst HAART visit; 52.9%were included in the com-
lete harm reduction category; 24.5% had a low dependence on
arm reduction, andonly 7%hadnodependence onharm reduction
t the ﬁrst HAART visit.l of Drug Policy 22 (2011) 210–218
Non-adherence, viral load and CD4 count
According to our deﬁnition, non-adherence in the past 6months
occurred during 11.9% of all visits. During the total studied period,
the rate of non-adherence ranged from a minimum rate of 6.2% (in
2002) to amaximum rate of 18.9% (in 2005) of the visits per year. Of
the 76 participants who were adherent on their ﬁrst included visit
and who had a follow-up visit, 26 became non-adherent at least
once in the study period. Fig. 1 shows that at 3 years the cumulative
incidence of non-adherencewas 32% (95%CI 20–43%) and at 7 years
it was 44% (95% CI 30–58%).
Table 2 shows that non-adherence was signiﬁcantly associated
with higher viral load level (p=0.008). This applies to both the
active injecting drug users in the no/incomplete HR intensity as
former injecting drug users in the low dependence on HR intensity.
There was no signiﬁcant association between non-adherence and
CD4 count.
Harm reduction intensity and determinants of non-adherence
Both univariate and multivariate analyses (Table 3) showed
no overall signiﬁcant effect of harm reduction intensity on
non-adherence (p=0.07 and 0.17 respectively). Interestingly, in
univariate analysis, drug users with low dependence on harm
reduction (i.e., non-injectors with low methadone dosing) seemed
to be more likely to be non-adherent to HAART, compared to drug
users with complete harm reduction (OR 2.03; 95% CI 1.12–3.69).
This trend remained in multivariate analysis (adjusted (a) OR 1.78;
95% CI 1.00–3.16).
Furthermore, drug users living in a situation without access to
structural support at home (unsupervised housing) were signiﬁ-
cantlymore likely to be non-adherent (aOR 2.58: 95% CI 1.40–4.73).
Participants having a steady partner in the last 6 months before an
ACS visit appeared to be less non-adherent than the participants
having no steady partner (aOR 0.48; 95% CI 0.24–0.96). Female par-
ticipants tended to be more non-adherent than male participants,
although the effect was borderline signiﬁcant (aOR 1.98: 95% CI
0.95–4.14).
Multivariate analysis determining the inﬂuence of each indi-
vidual component of harm reduction on non-adherence revealed
no signiﬁcant associations between any drug use (heroin, cocaine,
benzodiazepines or stimulants) and non-adherence. Participants
taking higher doses of methadone were signiﬁcantly more adher-
ent in univariate analysis (p=0.02) compared to participants taking
a lower dose of methadone (see Table 4), but this effect became
non-signiﬁcant in multivariate analysis. The effect of sex, steady
partner, housing situation and time period was comparable to
the model including harm reduction intensity, although the effect
of sex reached statistical signiﬁcance in the second multivariate
model.
Finally, since there was just a small number of visits in which
participants reported to have received no harm reduction at all, we
repeated our analysis without these visits in the harm reduction
variable. The results were not different from analysis with the total
group.
In sensitivity analysis, results also appeared to be comparable
when other criteria deﬁned non-adherence (less than 100% ofmed-
ication or less than 92% of medication taken).
DiscussionIn our longstanding cohort of drug users in Amsterdam, almost
all HIV-positive participants that receive HAART also rely on
methadone maintenance therapy. HIV-positive drug users not
receiving HAART are also less often receiving methadone treat-
F.A.E. Lambers et al. / International Journal of Drug Policy 22 (2011) 210–218 213
Table 1
Characteristics of HIV-positive drug users of the Amsterdam Cohort Studies using HAART between January 1999 and February 2009.
First visit All visits
N (%) N (%)
(number of persons =102) (number of visits = 733)
Sex
Female 31 (30.4%) 227 (31.0%)
Age at visit
Mean in years (SD) 42.3 (6.4) 44.1 (5.7)
≥29 and <40 42 (41.2%) 178 (24.3%)
≥40 and <50 48 (47.1%) 445 (60.7%)
≥50 12 (11.8%) 110 (15.0%)
Nationality
Non-Dutch 16 (15.7%) 86 (11.7%)
Educationa
Median in years (IQR) 4.0 (3.0) 4.0 (3.0)
≤1 year 10 (9.8%) 70 (9.6%)
1–7years 78 (76.5%) 550 (75.0%)
≥7years 14 (13.7%) 113 (15.4%)
Housing in past 6 months
Unsupervised housingb 76 (74.5%) 499 (68.4%)
Steady partner in past 6 months
Yes 41 (40.2%) 242 (33.0%)
Harm reduction intensity in past 6 months
No/incomplete 15 (14.7%)f 81 (11.1%)g
Complete 54 (52.9%) 452 (61.7%)
Low dependence 25 (24.5%) 153 (20.9%)
No dependence 7 (6.9%) 41 (5.6%)
Methadone usage in past 6 months
Yes 91 (89.2%) 683 (93.2%)
Methadone dosage in past 6 months
Median (IQR) 100mg/d (65mg/d) 100mg/d (80mg/d)
1–70mg/d 28 (27.5%) 198 (27.0%)
71–100mg/d 34 (33.3%) 184 (25.1%)
101–150mg/d 17 (16.7%) 140 (19.1%)
151–315mg/d 12 (11.8%) 161 (22.0%)
Needle exchange (NE) in past 6 months
No IDU, no NE 70 (68.6%) 551 (75.2%)
IDU, no NE 7 (6.9%) 26 (3.5%)
IDU, irregular NE 3 (2.9%) 10 (1.4%)
IDU, full NE 22 (21.6%) 143 (19.5%)
Any drug use in past 6 monthsc
Yes 76 (74.5%) 574 (78.3%)
Ever injected
Yes 94 (92.2%) 675 (92.1%)
Injected in past 6 months
Yes 32 (31.4%) 178 (24.3%)
Drug injected in past 6 months
Heroin
Yes 7 (6.9%) 42 (5.7%)
Cocaine
Yes 14 (13.7%) 89 (12.1%)
Heroin + cocaine (speedball)
Yes 18 (17.6%) 99 (13.5%)
Amphetamines
Yes 3 (3.0%) 16 (2.2%)
Non-injecting drug use in past 6 months
Heroin
Yes 40 (39.2%) 260 (35.5%)
Cocaine
Yes 60 (58.8%) 468 (64.6%)
Heroin + cocaine (speedball)
Yes 2 (1.9%) 10 (1.4%)
Amphetamines
Yes 0 (0.0%) 8 (1.1%)
Barbiturates
Yes 10 (9.9%) 134 (18.7%)
Tranquilizers (benzodiazepines)
Yesd 60 (59.4%) 421 (57.4%)
Viral load at visit
Median in copies/l (IQR) 400 (950) 400 (578)
CD4 count at visit
Median in cells/l (IQR) 250 (245) 260 (231)
Number of HAART visits in 1999–2009
Total 733
Median (IQR) NA 5 (6)
Time of follow-up since ﬁrst HAART visit from 1999
Median in years (IQR) NA 3(4.6)
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Table 1 (Continued)
First visit All visits
N (%) N (%)
(number of persons =102) (number of visits = 733)
Calendar-year of visit
Median (IQR) 2000 (1999–2002) 2002 (2000–2006)
Non-adherence to HAART in past 6 monthse
Yes 14 (13.7%) 87 (11.9%)
SD, standard deviation; IQR, inter quartile range.
a Number of years daily schooling after 12th year.
b Unsupervised: not living in single-bed occupancy shelter with structural support (e.g., renting own house). During this period, 7 participants reported being homeless at
1 visit, and 1 participant at 2 visits (total 1.4%). Because of this very low rate of homelessness, we included this category of housing situation within ‘unsupervised’ housing.
c Injecting heroin, cocaine, methadone, and heroin and cocaine together, and non-injecting use of heroine, cocaine and heroin and cocaine together.
d Reported use of benzodiazepines refers in most cases to benzodiazepines described b
e Non-adherence: taking less than 95% of prescribed HAART in the last 6 months.
f Of 15 visits (ﬁrst) in the No/Incomplete category, 3 were in the No and 12 in the Incom
g Of 81 visits (all) in the No/Incomplete category, 6 were in the No and 75 were in the I
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aig. 1. Cumulative incidence of non-adherence to HAART amongst drug users in the
CS from January 1999 until February 2009.ent, even though they showed more drug use. This conﬁrms
revious ﬁndings that the use of methadone lowers the barriers
o gain access to HAART (Clarke et al., 2003; Kapadia et al., 2008;
mit, Lindenburg, et al., 2006).
able 2
iral load and CD4 count stratiﬁed per harm reduction intensity and adherence.
HIV viral load Total group Non-adh
Percentage of visits
with viral load
>400×108 c/l
Percenta
with vira
>400×1
Overall 30% (177/594) 45% (33/
Harm reduction intensity
No/incomplete 20% (14/69) 60% (3/5
Complete 34% (125/365) 45% (19/
Low dependence 22% (27/125) 41% (9/2
No dependence 30% (10/33) 50% (2/4
CD4 count Median (IQR) Median
CD4 count×106 cells/l CD4 co
Overall 270 (250) 255 (3
Harm reduction intensity
No-incomplete 350 (290) 400 (3
Complete 270 (220) 270 (3
Low dependence 225 (233) 180 (2
No dependence 430 (300) 350 (2
QR, inter quartile range.
* p-Values were calculated using univariate logistic regression in a GEEmodel, comparin
bove and below 200 cells/l, between non-adherent and adherent visits.y physician and not illegal use.
plete group.
ncomplete group.
We hypothesized that HIV-positive drug users who access a
complete harm reduction programme aremore adherent toHAART
than those that do not. Interestingly though, we found that still-
injecting drug users receiving incomplete harm reduction can be
just as adherent. This might in part imply that participants of
this cohort are in general more socially stable and compliant. It
might also suggest that injecting drug use is not a barrier for
compliance in this cohort and it should therefore not be a bar-
rier for HIV-treatment. Furthermore, we found a tendency towards
more non-adherence amongst the drug users that are presumed to
have a lower dependence on harm reduction (i.e., non-injectors
with lower methadone dosing) than amongst drug users with
complete harm reduction including high methadone dosing. This
ﬁnding has been demonstrated previously (Moatti et al., 2000) and
could reﬂect a difference in kind of health care and frequency of
health care visits between those with (in)complete harm reduc-
tion and those with less dependence on harm reduction. More
importantly, it might be explained by a direct effect of methadone
dosing. Our model of the underlying individual components of the
harm reduction programmemight suggest that methadone dosage
could be of a certain relevance to adherence although the effect
of methadone dosage did not remain statistically signiﬁcant in
multivariate analysis. In our cohort, participants in the group less
dependent onharmreduction,with lowermethadonedosing,more
often receive their methadone treatment from their general prac-
titioner. Possibly, some general practitioners are not prescribing
erent Adherent p-Value
ge of visits
l load
08 c/l
Percentage of visits
with viral load
>400×108 c/l
73) 28% (142/515) 0.008*
) 17% (11/63) 0.036
42) 33% (104/320) 0.006
2) 18% (18/101) 0.863
) 28% (8/29) 0.196
(IQR) Median (IQR)
unt×106 cells/l CD4 count×106 cells/l
20) 280 (240) 0.395*
37) 350 (293) 0.260
60) 207 (220) 0.656
50) 250 (238) 0.042
90) 430 (327) –
g the percentages of viral load below and above 400 c/l and comparing CD4 count
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Table 3
Prevalence of HAART non-adherence, and uni- and multivariate analyses of determinants of non-adherence amongst drug users of the ACS between January 1999 and
February 2009, with harm reduction intensity and calendar year as ﬁxed variables.
Prevalence non-adherence (%) (n/visits) OR (95% CI) Overall p-value aOR (95% CI) Overall p-value
Sex 0.066 0.068
Male 9.8 (49/501) 1 1
Female 16.9 (38/225) 1.84 (0.96–3.52) 1.98 (0.95–4.14)
Age at visit 0.90
≥29 and <40 years 10.1 (18/178) 1
≥40 and < 50 years 12.5 (55/439) 1.15 (0.59–2.25)
≥50 years 12.8 (14/109) 1.18 (0.53–2.60)
Nationality 0.26
Dutch 11.2 (72/641) 1
Non-Dutch 17.7 (15/85) 1.76 (0.66–4.72)
Education* 0.53
≤1 year 18.6 (13/70) 1
1–7years 12.5 (68/544) 0.81 (0.27–2.45)
≥7years 5.4 (6/112) 0.46 (0.10–2.02)
Housing in past 6 months 0.003 0.002
Supervised 7.0 (16/229) 1 1
Unsupervised housing** 14.2 (70/494) 2.44 (1.36–4.36) 2.58 (1.40–4.73)
Steady partner in past 6 months 0.41 0.039
No 12.4 (60/483) 1
Yes 11.3 (27/240) 0.79 (0.44–1.40) 0.48 (0.24–0.96)
Harm reduction intensityin past 6 months 0.071 0.17
No/incomplete 11.4 (6/80) 0.87 (0.35–2.18) 0.76 (0.29–2.04)
Complete 7.5 (51/449) 1 1
Low dependence 16.0 (24/150) 2.03 (1.12–3.69) 1.78 (1.00–3.16)
No dependence 12.2 (5/41) 1.67 (0.66–4.24) 1.55 (0.51–4.72)
Methadone usage in past 6 months 0.90
No 10.9 (5/46) 1
Yes 12.1 (82/677) 1.07 (0.38–3.06)
Methadone dosage in past 6 months 0.021
1–70mg/d 14.9 (29/195) 1
71–100mg/d 9.8 (18/183) 0.43 (0.20–0.91)
101–150mg/d 11.5 (16/139) 0.47 (0.22–1.01)
150–315mg/d 11.9 (19/160) 0.36 (0.10–1.25)
Needle exchange (NE) in past 6 months 0.35
No IDU, no NE 13.0 (71/545) 1
IDU, no NE 7.7 (2/26) 0.50 (0.13–1.96)
IDU, irregular NE 22.2 (2/9) 1.17 (0.20–6.90)
IDU, full NE 7.7 (11/143) 0.42 (0.16–1.13)
Any drug use*** in past 6 months 0.90
No 13.0 (20/154) 1
Yes 11.6 (66/568) 1.05 (0.50–2.20)
Ever injected 0.77
No 12.5 (7/56) 1
Yes 12.0 (80/688) 1.17 (0.48–2.91)
Injected in past 6 months 0.13
No 13.0 (71/546) 1
Yes 8.5 (15/177) 0.49 (0.19–1.24)
Drug injected in past 6 months
Heroin 0.14
No 11.1 (74/669) 1
Yes 23.8 (10/42) 2.07 (0.79–5.45)
Cocaine 0.024
No 12.8 (80/623) 1
Yes 4.5 (4/89) 0.21 (0.05–0.81)
Heroin + cocaine (speedball) 0.30
No 12.3 (76/614) 1
Yes 9.2 (9/98) 0.63 (0.26–1.51)
Amphetamines
No 12.1 (84/696)
Yes 0 (0/16) – –
Non-injecting drug use in past 6 months
Heroin 0.20
No 10.6 (48/452)
Yes 13.9 (36/259) 1.41 (0.83–2.39)
Cocaine 0.31
No 11.1 (28/253) 1
Yes 12.5 (58/464) 1.34 (0.76–2.36)
Heroin + cocaine (speedball) 0.72
No 11.8 (83/701) 1
Yes 10.0 (1/10) 0.67 (0.07–6.350
Amphetamines 0.95
No 11.8 (83/705) 1
Yes 12.5 (1/8) 0.95 (0.20–4.55)
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Table 3 (Continued)
Prevalence
non-adherence (%)
(n/visits)
OR (95% CI) Overall p-value aOR (95% CI) Overall p-value
Barbiturates 0.45
No 11.9 (69/578) 1
Yes 11.3 (15/133) 0.75 (0.36–1.57)
Tranquilizers**** (benzodiazepines) 0.95
No 11.2 (34/303) 1
Yes 12.5 (52/415) 0.98 (0.59–1.65)
Viral load at visit 0.014
<400 copies/l 9.7 (40/413) 1
≥400 copies/l 18.9 (33/175) 2.35 (1.28–4.29)
Missing 10.1 (14/138) 0.93 (0.46–1.86)
CD4 count at visit 0.30
<200 14.8 (31/210) 1
≥200 11.1 (44/397) 0.70 (0.40–1.21)
Missing 10.1 (12/119) 0.54 (0.23–1.27)
Calendar-year of visit 0.99 (0.90–1.08) 0.81 1.00 (0.91–1.10) 1.00
*Number of years daily scholing after 12th year.
**Unsupervised: not living in single-bed occupancy shelter with structural support (e.g., renting own house). During this period, 7 participants reported being homeless at 1
visit, and 1 participant at 2 visits (total 1.4%). Because of this very low rate of homelessness, we included this category of housing situation within ‘unsupervised’ housing.
***Injecting heroin, cocaine, methadone, and heroin and cocaine together, and non-injecting use of heroine, cocaine and heroin and cocaine together.
****Reported use of benzodiazepines refers in most cases to benzodiazepines described by physician and not illegal use.
Table 4
Prevalence of HAART non-adherence, and uni- and multivariate analyses of determinants of non-adherence amongst drug users of the ACS between January 1999 and
February 2009, with methadone dosage and calendar year as ﬁxed variables.
Prevalence
non-adherence (%)
(n/visits)
OR (95% CI) Overall p-value aOR (95% CI) Overall p-value
Methadone dosage in past 6 months 0.021 0.13
1–70mg 14.9 (29/195) 1 1
71–100mg 9.9 (18/183) 0.43 (0.20–0.92) 0.51 (0.25–1.06)
101–150mg 11.5 (16/139) 0.47 (0.22–1.01) 0.61 (0.27–1.34)
151–315mg 11.9 (19/160) 0.36 (0.10–1.25) 0.45 (0.14–1.47)
Sex 0.066 0.038
Male 9.8 (49/501) 1 1
Female 16.9 (38/225) 1.84 (0.96–3.52) 2.24 (1.05–4.82)
Steady partner in past 6 months 0.41 0.039
No 12.4 (60/483) 1 1
Yes 11.3 (27/240) 0.79 (0.44–1.40) 0.46 (0.22–0.96)
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heir patients on HAART a high enoughmethadone dosage, despite
eports that drug users on certain combinations of HAART need an
ncreaseddosageofmethadonedue to itspharmaco-dynamic inter-
ction with HAART (Arroyo et al., 2007; Clarke et al., 2001). It also
mplies that close monitoring of patients that use both HAART and
ethadone is essential to prevent the detrimental consequences of
too-lowmethadone dosage (Tossonian et al., 2007). Furthermore,
sing interventions such as directly administered antiretroviral
herapy could attribute to the increase of adherence amongst all
ind of drug users (Altice et al., 2004).
In addition, we studied variables other than harm reduction as
ossible determinants of HAART adherence. Firstly, the importance
f a systematic support system was emphasized by the indepen-
ent association of unsupervised housing with non-adherence and
ot having a steady partner with non-adherence. A review by
eaver et al. emphasized the ‘impact of affordable and sustainable
ousing on the health of persons living with HIV’ (Leaver et al.,
007). With our results, we add the importance of having more
ealth care monitoring close to home. The increased adherence of
articipantswho live in a settingwhere theyhaveaccess to support,
uch as a single-room-occupancy-shelter, probably reﬂects in part
he direct observation of treatment, that is implemented in such
ousing in Amsterdam. Having a steady partner presumably leads0.003 0.001
1
) 2.74 (1.48–5.07)
8) 0.81 1.00 (0.91–1.09) 1.00
to better adherence through social support (Carrieri et al., 2006;
Knowlton et al., 2007), and a steady partner can help by remind-
ing to take medication and by encouragement. Overall, social and
structural factors that improve or decrease adherence should gain
more attention (Krusi, Wood, Montaner, & Kerr, 2010).
Secondly, in adjusted analyses we found no statistically signif-
icant proof of the direct inﬂuence of heroin, cocaine or other drug
use on HAART adherence, even though we looked at the manner
of use and sort of drug used singly and in combinations (data not
shown). Obviously, in our cohort of drug users, the prevalence of
injecting drugs compared to smoking or snifﬁng drugs is relatively
low and might therefore have a less noticeable effect on adher-
ence. In the same way, the high prevalence of non-injecting drug
use might make it difﬁcult to reveal its effect on HAART adherence
in this population.
This study gains its strength from data collection over a period
of ten years and the detailed data on harm reduction that allowed
study of its speciﬁc inﬂuence on adherence.
A limitation is the limited sample size andmore speciﬁc thenear
absence of a separate group of injecting drug users who receive
no harm reduction and are on HAART. Using such a group as a
reference would make it possible to study the inﬂuence of harm
reduction in general. However, denying drug users harm reduction
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or study purposes in a setting where harm reduction is available
ould be unethical. We were nevertheless able to differentiate
etween intensities of harm reduction to test our hypothesis. Inter-
stingly, the relatively small no harm reduction group appears less
ikely to initiate HAART in Amsterdam (Smit, Lindenburg, et al.,
006), suggesting that, besides receiving methadone, certain drug
sers’ characteristicsmight inﬂuence access toharmreductionpro-
rammes and HIV care.
Another limitation is that the data on adherence are based on
elf-report, and over- or underreporting thus cannot be excluded.
owever, the fact that non-adherent participants had a signiﬁcant
igher viral load than participants in the adherent group indicates
hat the reporteddata are generally reliable. Also, participantswere
ot interviewed by their HIV healthcare-provider or methadone
rovider but by independent researchers outside these settings,
ho are less likely to elicit socially desirable answers. Further-
ore, we showed that, when adherent, active drug users in the
o/incomplete HR group can achieve similar viral load suppression
s less active or former drug users in the less dependence on HR
roup (see Table 2). Important factors such as time on HAART or
adir CD4 count were not taken into account though. Finally, we
annot exclude selection bias. The participation of the patients in
ur cohort may indicate that they are more aware of their health
ompared to patients not participating in the cohort.
In conclusion, this study suggests that HIV-positive injecting
rug users participating in a harm reduction programme can be
t least as adherent to HIV treatment as non-injecting drug users
ith no dependence on harm reduction. Furthermore, it appears
o be important for non-injecting drug users less dependent on
ethadone to continue participation in a harm reduction pro-
ramme, with speciﬁcally a sufﬁcient methadone dosage, to keep
hem adherent to HAART. This study stresses the importance of
ffering all drug users systematic and comprehensive care (Lert &
azatchkine, 2007; Malta, Strathdee, Magnanini, & Bastos, 2008;
pire, Lucas, & Carrieri, 2007), in which substance abuse treat-
ent, psychiatric treatment, and social support are integrated. The
ntegration of HIV care within such a system is likely to increase
oth HAART uptake and adherence. Finally, our ﬁndings suggest
hat when comprehensive harm reduction programmes are imple-
ented in settings with a high prevalence of injecting drug users,
uch as Eastern-Europe or Asia, access to HAART can and should
lso be increased for this speciﬁc population.
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